Company / Cash & Equivalents
ResMed Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.2B
FY2025
5-year range
$227.9M / $1.2B
FY2021-FY2025
Trend
+407.4%
vs FY2024
Sector context
#27 of 152
Health Care
What the data says
Cash & Equivalents changed +407% YoY in FY2025, a notable deviation from the 9-year average annual change of +53%.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +21.2%. Top quartile in the Health Care sector.
Improved from $228M to $1.2B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +64.1%
- 5-Year CAGR
- +21.2%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 152This company $1.2B Sector average $1.2B
▼
+3.9% above sector average
Key checks
Key Insights
- 5-year CAGR of +21.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 407.4% year-over-year.
- Ranks #27 out of 152 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2019.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +407.4% |
| FY2024 | $238.4M | +4.6% |
| FY2023 | $227.9M | -16.7% |
| FY2022 | $273.7M | -7.3% |
| FY2021 | $295.3M | -36.2% |
| FY2020 | $463.2M | +214.8% |
| FY2019 | $147.1M | -22.0% |
| FY2018 | $188.7M | -77.0% |
| FY2017 | $821.9M | +12.4% |
| FY2016 | $731.4M | +2.0% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026